Related Experiment Videos
Cardiovascular risk and TZD: safe therapy for the elderly?
Rebecca Burt1, Sarah Townsend, Becky Armor
1University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73126, USA. becky-armor@ouhsc.edu
Summary
Thiazolidinedione drugs like rosiglitazone may pose cardiovascular risks. Pharmacists play a key role in clarifying these safety concerns for elderly patients with diabetes.
Area of Science:
- Pharmacology
- Cardiology
- Geriatrics
Background:
- Cardiovascular risks associated with thiazolidinedione (TZD) therapy, including rosiglitazone and pioglitazone, are a significant safety concern.
- Conflicting research exists regarding the association between rosiglitazone and adverse cardiovascular events like myocardial infarction and death.
- Comorbidities such as heart failure and renal insufficiency limit treatment options for elderly patients with diabetes, a population with a high prevalence of the disease.
Purpose of the Study:
- To review the safety concerns of thiazolidinedione therapy, particularly in the context of cardiovascular risks.
- To highlight the importance of pharmacists in addressing patient and public misconceptions about TZD safety.
Main Methods:
- Review of recent data and research findings on thiazolidinedione cardiovascular safety.
- Analysis of studies reporting increased or no increased risk of myocardial infarction and death with rosiglitazone.
- Consideration of treatment limitations in elderly patients with diabetes and comorbidities.
Main Results:
- Conflicting evidence exists regarding the cardiovascular safety of rosiglitazone, with some studies indicating increased risks and others showing no significant association.
- Elderly patients with diabetes often have comorbidities that restrict their treatment choices.
- Media reporting on research can lead to misinterpretation by the public.
Conclusions:
- Pharmacists are essential in providing accurate information and addressing safety concerns related to thiazolidinediones for patients, especially the elderly.
- Understanding the nuances of cardiovascular risk data for rosiglitazone and pioglitazone is crucial for safe diabetes management.
- Clear communication from healthcare professionals is vital to counteract potential public misinformation regarding drug safety.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...